$CRIS
CURIS INC

2014 Q1 Form 10-K Financial Statement

#000119312514097662 Filed on March 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $1.285M $15.00M $1.686M
YoY Change 47.42% -11.61% -88.03%
Cost Of Revenue $70.00K $200.0K $9.530M
YoY Change 133.33% -97.93%
Gross Profit $1.220M $14.80M -$7.840M
YoY Change 45.24% 102.74%
Gross Profit Margin 94.97% 98.65% -464.89%
Selling, General & Admin $2.830M $11.29M $2.880M
YoY Change 10.12% 8.35% 38.46%
% of Gross Profit 231.97% 76.28%
Research & Development $3.146M $12.93M $9.500M
YoY Change 19.69% -16.56% 113.48%
% of Gross Profit 257.86% 87.34%
Depreciation & Amortization $40.00K $140.0K $40.00K
YoY Change 33.33% 7.69% 33.33%
% of Gross Profit 3.28% 0.95%
Operating Expenses $3.146M $12.93M $9.500M
YoY Change 19.69% -16.56% 45.71%
Operating Profit -$4.753M -$9.416M -$17.34M
YoY Change 9.09% -49.43%
Interest Expense $951.0K $3.842M $1.060M
YoY Change 0.33% 1781.62% -170.67%
% of Operating Profit
Other Income/Expense, Net -$810.6K -$2.906M
YoY Change 34.0% -231.9%
Pretax Income -$5.560M -$12.32M -$12.37M
YoY Change 12.1% -24.97% -304.13%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.564M -$12.32M -$12.37M
YoY Change 12.12% -24.94% -304.15%
Net Earnings / Revenue -433.11% -82.14% -733.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$323.6K -$748.0K -$773.1K
COMMON SHARES
Basic Shares Outstanding 85.95M shares 79.97M shares
Diluted Shares Outstanding 79.97M shares

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.80M $58.20M $55.50M
YoY Change 14.46% 4.86% 47.21%
Cash & Equivalents $7.908M $9.600M $12.75M
Short-Term Investments $49.90M $48.60M $42.80M
Other Short-Term Assets $500.0K $500.0K $400.0K
YoY Change 25.0% 25.0% -42.86%
Inventory
Prepaid Expenses
Receivables $1.369M $1.500M $908.1K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $59.65M $60.20M $56.85M
YoY Change 15.37% 5.8% 47.67%
LONG-TERM ASSETS
Property, Plant & Equipment $408.6K $400.0K $434.2K
YoY Change 2.16% 0.0% -13.17%
Goodwill $8.982M $8.982M
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.100M $10.70M $3.200M
YoY Change 64.86% 234.38%
Other Assets $91.17K $300.0K $157.8K
YoY Change -69.61% 0.0% -21.08%
Total Long-Term Assets $15.72M $20.40M $12.92M
YoY Change 17.28% 58.14% 33.16%
TOTAL ASSETS
Total Short-Term Assets $59.65M $60.20M $56.85M
Total Long-Term Assets $15.72M $20.40M $12.92M
Total Assets $75.36M $80.60M $69.77M
YoY Change 15.77% 15.47% 44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.545M $2.000M $2.504M
YoY Change 15.68% -20.0% 4.34%
Accrued Expenses $1.246M $1.900M $1.475M
YoY Change 3.85% 26.67% 5.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.392M $2.600M
YoY Change 1030.81%
Total Short-Term Liabilities $7.809M $6.600M $3.979M
YoY Change 116.91% 65.0% 4.71%
LONG-TERM LIABILITIES
Long-Term Debt $26.82M $27.90M $29.84M
YoY Change -10.59% -6.38%
Other Long-Term Liabilities $194.7K $900.0K $194.9K
YoY Change -83.77% -47.06% -95.67%
Total Long-Term Liabilities $27.02M $28.80M $30.03M
YoY Change -13.41% -8.57% 567.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.809M $6.600M $3.979M
Total Long-Term Liabilities $27.02M $28.80M $30.03M
Total Liabilities $34.83M $35.40M $35.50M
YoY Change 0.08% -0.28% 327.72%
SHAREHOLDERS EQUITY
Retained Earnings -$766.4M -$748.5M
YoY Change
Common Stock $871.7K $810.7K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.524M $891.3K
YoY Change 0.0%
Treasury Stock Shares 1.223M shares 1.048M shares
Shareholders Equity $40.54M $45.20M $34.27M
YoY Change
Total Liabilities & Shareholders Equity $75.36M $80.60M $69.77M
YoY Change 15.77% 15.47% 44.75%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$5.564M -$12.32M -$12.37M
YoY Change 12.12% -24.94% -304.15%
Depreciation, Depletion And Amortization $40.00K $140.0K $40.00K
YoY Change 33.33% 7.69% 33.33%
Cash From Operating Activities -$5.310M -$9.540M -$13.71M
YoY Change 22.63% -37.21% -257.77%
INVESTING ACTIVITIES
Capital Expenditures $153.0K -$60.00K
YoY Change 45.76% 500.0%
Acquisitions
YoY Change
Other Investing Activities $3.440M -$13.46M -$11.68M
YoY Change 164.62% -41.22% 93.38%
Cash From Investing Activities $3.440M -$13.62M -$11.73M
YoY Change 173.02% -40.8% 93.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $180.4K $16.25M
YoY Change -39.39% 218.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 180.0K 20.00M 30.39M
YoY Change 350.0% -44.17% 4965.0%
NET CHANGE
Cash From Operating Activities -5.310M -9.540M -13.71M
Cash From Investing Activities 3.440M -13.62M -11.73M
Cash From Financing Activities 180.0K 20.00M 30.39M
Net Change In Cash -1.690M -3.156M 4.950M
YoY Change -44.22% 33.06% 52.78%
FREE CASH FLOW
Cash From Operating Activities -$5.310M -$9.540M -$13.71M
Capital Expenditures $153.0K -$60.00K
Free Cash Flow -$5.310M -$9.693M -$13.65M
YoY Change 21.65% -36.64% -256.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85948078 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
182906000
CY2010Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1612322 shares
CY2010Q1 cris Registered Direct Offering Number Of Common Stock Per Unit
RegisteredDirectOfferingNumberOfCommonStockPerUnit
1
CY2010Q1 cris Registered Direct Offering Units
RegisteredDirectOfferingUnits
6449288 shares
CY2010Q1 cris Registered Direct Offering Number Of Warrant Per Unit
RegisteredDirectOfferingNumberOfWarrantPerUnit
1
CY2010Q1 cris Direct Offering Purchase Price
DirectOfferingPurchasePrice
2.52
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
45517657
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7826549
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
39875957
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4361168
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15119730
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80017781 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8134191 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81065488 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.59
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10437761 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.30
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1047707 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1474556
CY2012Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29838925
CY2012Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
999038
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2100837
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
143851
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
782837507
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2504270
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
127500
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
109614000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3978826
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15159
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
194921
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
34267498
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1488179
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-748504549
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
810655
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69768349
CY2012Q4 us-gaap Liabilities
Liabilities
35500851
CY2012Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
615859
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
204167
CY2012Q4 us-gaap Liabilities Fair Value Disclosure Nonrecurring
LiabilitiesFairValueDisclosureNonrecurring
0
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42791689
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
3162025
CY2012Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
109572000
CY2012Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
13877
CY2012Q4 us-gaap Assets Current
AssetsCurrent
56851903
CY2012Q4 us-gaap Goodwill
Goodwill
8982000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
42775952
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
27269000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157848
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67737000
CY2012Q4 us-gaap Restricted Investments
RestrictedInvestments
194282
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
109614000
CY2012Q4 us-gaap Assets
Assets
69768349
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12747709
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
908064
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2535005
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10538000
CY2012Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
203887
CY2012Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
180405
CY2012Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
64000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
707000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
390564
CY2012Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
42000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
59000
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
716786
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-760826561
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2012Q4 us-gaap Assets Fair Value Disclosure Nonrecurring
AssetsFairValueDisclosureNonrecurring
0
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
42791689
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
891274
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
434168
CY2012Q4 cris Deferred Finance Non Current Costs
DeferredFinanceNonCurrentCosts
154868
CY2012Q4 cris Accrued Liabilities Against Accrued Interest Net
AccruedLiabilitiesAgainstAccruedInterestNet
50984
CY2012Q4 cris Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
2809000
CY2012Q4 cris Deferred Finance Current Costs
DeferredFinanceCurrentCosts
49019
CY2012Q4 cris Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
490000
CY2012Q4 cris Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
15737
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85859016 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6884869 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1373517 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87081862 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.79
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10077805 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.44
CY2013Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
24529 sqft
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1222846 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
3.55
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1911479
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
651000
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
28050291
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27945186
CY2013Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1267954
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1913429
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178390
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
806660340
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2713000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2036864
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
166200
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
700000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
114904000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6558517
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6984
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
196734
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
45173585
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
870819
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2610174
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80590808
CY2013Q4 us-gaap Liabilities
Liabilities
35417223
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
676000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
298935
CY2013Q4 us-gaap Liabilities Fair Value Disclosure Nonrecurring
LiabilitiesFairValueDisclosureNonrecurring
0
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
627000
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48588135
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
10726685
CY2013Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
114869000
CY2013Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
13877
CY2013Q4 us-gaap Assets Current
AssetsCurrent
60165947
CY2013Q4 us-gaap Goodwill
Goodwill
8982000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
47592763
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
23711000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104034
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72446000
CY2013Q4 us-gaap Restricted Investments
RestrictedInvestments
180364
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
114904000
CY2013Q4 us-gaap Assets
Assets
80590808
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9591487
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1477188
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2359084
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11588000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5831000
CY2013Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
152496
CY2013Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
166487
CY2013Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
120000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
118000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
495260
CY2013Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
35000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5979000
CY2013Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
1001802
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4987000
CY2013Q4 us-gaap Assets Fair Value Disclosure Nonrecurring
AssetsFairValueDisclosureNonrecurring
0
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
47586333
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1524029
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
445655
CY2013Q4 cris Deferred Finance Non Current Costs
DeferredFinanceNonCurrentCosts
101055
CY2013Q4 cris Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber
9920751 shares
CY2013Q4 cris Deferred Finance Current Costs
DeferredFinanceCurrentCosts
51441
CY2013Q4 cris Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
3891000
CY2013Q4 cris Operating Lease Cash Obligation
OperatingLeaseCashObligation
4401000
CY2013Q4 cris Stock Issued During Period Due To Exercise Of Warrants
StockIssuedDuringPeriodDueToExerciseOfWarrants
238805 shares
CY2013Q4 cris Deferred Tax Assets Tax Deferred Interest Expense
DeferredTaxAssetsTaxDeferredInterestExpense
307000
CY2013Q4 cris Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
2.78
CY2013Q4 cris Debt Instrument Current Carrying Amount
DebtInstrumentCurrentCarryingAmount
2663677
CY2013Q4 cris Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
2723000
CY2013Q4 cris Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
15476
CY2013Q4 cris Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
9046
CY2002Q2 us-gaap Stock Repurchase Program Authorized Amount
StockRepurchaseProgramAuthorizedAmount
3000000
CY2002 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1047707 shares
CY2002 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
891274
CY2010 cris Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
14942317
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1641830 shares
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.249 pure
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76351856 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.019 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.72
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4563297
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.004 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12705059 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.054 pure
CY2011 us-gaap Revenues
Revenues
14762580
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-24111
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9870292
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1504000
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42136949
CY2011 us-gaap Licenses Revenue
LicensesRevenue
14300000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
100034
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11397
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-7202503
CY2011 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
77068
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-50304
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2656392
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-9858895
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
416196
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-246122
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1641830
CY2011 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2011 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2456481
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
260405
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-261090
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11397
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2756426
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
21965083
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8272424
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2080820
CY2011 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2011 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
77068
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2129000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
1772111
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
107396
CY2011 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
5295598
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7293181
CY2011 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
145000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1792003
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9775658
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13692659
CY2011 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2011 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2011 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
51834854
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2011 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.173 pure
CY2011 cris Percentage Research And Development Expenses
PercentageResearchAndDevelopmentExpenses
0.05 pure
CY2011 cris Adjustments To Additional Paid In Capital Stock Issued Under Atm Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedUnderAtmIssuanceCosts
128155
CY2011 cris Receivable For Issuances Of Common Stock
ReceivableForIssuancesOfCommonStock
375661
CY2011 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
462580
CY2011 cris Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
288817
CY2011 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
418000
CY2011 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
130281
CY2013 dei Entity Registrant Name
EntityRegistrantName
CURIS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001108205
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
0 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.90
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1102003 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(1)</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>OPERATIONS</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">Curis, Inc. is an oncology-focused drug development company seeking to develop novel, targeted drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term &#x201C;the Company&#x201D; refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#x201C;Curis&#x201D; refers to Curis, Inc.</font></p> <p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways in seeking to develop targeted drug candidates including CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins, which is currently subject to a U.S. Food and Drug Administration, or FDA, partial clinical hold, and CUDC-907, a dual histone deacetylase, or HDAC, and phosphoinostide-3 kinase, or PI3K, inhibitor. Erivedge<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. The Company&#x2019;s licensee Debiopharm is advancing the clinical development of the heat shock protein 90, or HSP90, inhibitor, Debio 0932.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company&#x2019;s business, including, but not limited to: the Company&#x2019;s reliance on Genentech and Roche to successfully commercialize Erivedge; the Company&#x2019;s ability to advance and expand its research and development programs, including whether the FDA lifts the partial clinical hold placed on CUDC-427; the Company&#x2019;s ability to obtain adequate financing to fund its operations; the ability of the Company&#x2019;s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.&#xE0; r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company&#x2019;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#x2019;s competitors of new or better technological innovations; dependence on key personnel; the Company&#x2019;s ability to comply with regulatory requirements; and the Company&#x2019;s ability to execute on its overall business strategies.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s future operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company&#x2019;s operations will vary significantly from year to year and quarter to quarter and depend on, a number of factors, including, but not limited to: Roche and Genentech&#x2019;s ability to successfully commercialize Erivedge; positive results in Genentech&#x2019;s ongoing clinical trials; the timing, outcome and cost of the Company&#x2019;s preclinical studies and clinical trials for its drug candidates; whether or not the FDA removes the partial clinical hold on CUDC-427; and the Company&#x2019;s ability to successfully enter into one or more material licenses or collaboration agreements for its proprietary drug candidates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 8%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company anticipates that existing cash, cash equivalents and investments at December&#xA0;31, 2013 should enable it to maintain current and planned operations for the foreseeable future. The Company&#x2019;s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech, Debiopharm and the Leukemia&#xA0;&amp; Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</font></p> </div>
CY2013 us-gaap Interest Expense
InterestExpense
3841646
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4016383
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2651152 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.430 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82339493 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.44
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.27
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9539577
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13617537
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12926834
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.12
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2861000 shares
CY2013 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-01-31
CY2013 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2118953 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(m)</td> <td valign="top" align="left">CONCENTRATION OF RISK</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, marketable securities and long-term investments. The Company invests directly in commercial paper of financial institutions and corporations with A-/Aa3 or better long-term ratings and A-1/P-1 short term debt ratings and U.S. Treasury securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#x2019;s credit risk related to marketable securities and long-term investments is reduced as a result of the Company&#x2019;s policy to limit the amount invested in any one issue.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s accounts receivable at December&#xA0;31, 2013, represents amounts due from collaborators, primarily for royalties earned on sales of Erivedge by Genentech and Roche.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company relies on third parties to supply certain raw materials necessary to produce its drug candidates, including CUDC-907 and CUDC-427, for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that the Company uses to manufacture its drug candidates.</p> </div>
CY2013 us-gaap Royalty Expense
RoyaltyExpense
197796
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
104842
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
39671
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-771393
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
24418441
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11293811
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000892
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.008 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11451322 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">USE OF ESTIMATES</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The preparation of the Company&#x2019;s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include revenue recognition, including estimates of the performance obligations under the Company&#x2019;s collaboration agreements; the estimated repayment term of the Company&#x2019;s debt and related short- and long-term classification; the collectibility of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company&#x2019;s valuation of stock-based compensation and the value of certain investments and liabilities, including our warrant liability. Actual results may differ from such estimates.</p> </div>
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
713968
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2013 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
632755
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2091000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3002241
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
141522
CY2013 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
2782435
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3156222
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
145000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.085 pure
CY2013 us-gaap Revenues
Revenues
15002032
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
116639
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12344155
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2716000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
65827658
CY2013 us-gaap Repayments Of Debt
RepaymentsOfDebt
2928068
CY2013 us-gaap Licenses Revenue
LicensesRevenue
10000000
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
261475
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
164650
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-22143
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-9416409
CY2013 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
1273
CY2013 us-gaap Interest Paid
InterestPaid
2913999
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
569124
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2905603
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-12322012
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-95197
CY2013 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
753639
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2651152
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
3942136
CY2013 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
20880756
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153009
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-13918
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22143
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
181821
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
52349212
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2013 cris Number Of Operating Leases
NumberOfOperatingLeases
1 CreditFacility
CY2013 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.052 pure
CY2013 cris Additional Period For Lease
AdditionalPeriodForLease
P5Y
CY2013 cris Share Based Compensation Plans
ShareBasedCompensationPlans
2 Plans
CY2013 cris Percentage Research And Development Expenses
PercentageResearchAndDevelopmentExpenses
0.05 pure
CY2013 cris Obligation Limit
ObligationLimit
2.5 pure
CY2013 cris Payments To Related Party
PaymentsToRelatedParty
0
CY2013 cris Tax Credit Carryforward Expiration
TaxCreditCarryforwardExpiration
Starting in 2018 through 2033
CY2013 cris Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
P4M21D
CY2013 cris Treasury Stock Non Cash
TreasuryStockNonCash
632755
CY2013 cris Debt Issuance Costs Gross
DebtIssuanceCostsGross
421715
CY2013 cris Diligence Period
DiligencePeriod
P5Y
CY2013 cris Tax Credit Carryforward Beginning Expiration Year
TaxCreditCarryforwardBeginningExpirationYear
2018
CY2013 cris Contingent Obligations
ContingentObligations
4125000
CY2013 cris Adjustments To Additional Paid In Capital Stock Issued Under Atm Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedUnderAtmIssuanceCosts
641052
CY2013 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
1059896
CY2013 cris Scientific Advisory Agreement Effective Date
ScientificAdvisoryAgreementEffectiveDate
2006-09-13
CY2013 cris Consulting Agreement Date
ConsultingAgreementDate
2012-03-01
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-40959
CY2012 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
964000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16435713
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2525000
CY2013 cris Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
16245984
CY2013 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
329000
CY2013 cris Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
-0.025 pure
CY2013 cris Net Operating Losses Expiration Year
NetOperatingLossesExpirationYear
2013
CY2013 cris Tax Credit Carryforward Ending Expiration Year
TaxCreditCarryforwardEndingExpirationYear
2033
CY2013 cris Term Of Warrants Period
TermOfWarrantsPeriod
P5Y
CY2013 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
351089
CY2013 cris Effective Income Tax Rate Reconciliation Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationFairValueOfWarrants
0.021 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3268689 shares
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.050 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79059153 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.017 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.99
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15193305
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.021 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11811278 shares
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69153956
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008 pure
CY2012 us-gaap Revenues
Revenues
16971991
CY2012 us-gaap Licenses Revenue
LicensesRevenue
14000000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
160240
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
149937
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18806
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-18619807
CY2012 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
177
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
865997
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2202900
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-16416907
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
434763
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3268689
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
1529644
CY2012 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6239343
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
104975
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-41632
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18806
CY2012 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
30000000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20316
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2257130
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
35591798
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10423014
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35824539
CY2012 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6415000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
3623911
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
126537
CY2012 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1223602
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2372021
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
153000
CY2012 us-gaap Interest Expense
InterestExpense
204167
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5105699
CY2012 us-gaap Royalty Expense
RoyaltyExpense
176482
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23003255
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15492302
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2012 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
9500000
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5769
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46214044
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
614000
CY2012 cris Effective Income Tax Reconciliation Net Operating Loss Expirations
EffectiveIncomeTaxReconciliationNetOperatingLossExpirations
-0.360 pure
CY2012 cris Payments To Related Party
PaymentsToRelatedParty
133333
CY2012 cris Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
P5M6D
CY2012 cris Number Of University Licensors
NumberOfUniversityLicensors
2 Licensors
CY2012 cris Change In Fair Value Upon Warrant Exercise
ChangeInFairValueUponWarrantExercise
615859
CY2012 cris Adjustments To Additional Paid In Capital Stock Issued Under Atm Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedUnderAtmIssuanceCosts
27356
CY2012 cris Receivable For Issuances Of Common Stock
ReceivableForIssuancesOfCommonStock
14366
CY2012 cris Research And Development Revenue
ResearchAndDevelopmentRevenue
1442347
CY2012 cris Maximum Financial Support To Related Party
MaximumFinancialSupportToRelatedParty
400000
CY2012 cris Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
879080
CY2012 cris Written Off Plant And Equipment Net Of Accumulated Depreciation
WrittenOffPlantAndEquipmentNetOfAccumulatedDepreciation
418000
CY2012 cris Issuance Of Common Stock To Licensees
IssuanceOfCommonStockToLicensees
964000
CY2012 cris Debt Issuance Costs Unpaid And Accrued
DebtIssuanceCostsUnpaidAndAccrued
261475
CY2012 cris Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees
355222
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.06
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80096650 shares
CY2013Q1 us-gaap Revenues
Revenues
871435
CY2013Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4357364
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-4962294
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83336695 shares
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.03
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77556366 shares
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.03
CY2012Q1 us-gaap Revenues
Revenues
10356252
CY2012Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
2199695
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
2225737
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79052517 shares
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.04
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79052517 shares
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.04
CY2012Q2 us-gaap Revenues
Revenues
4351574
CY2012Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2426105
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-2886452
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.02
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81128475 shares
CY2013Q2 us-gaap Revenues
Revenues
5404377
CY2013Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-706196
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1293848
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79639433 shares
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.04
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79639433 shares
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.04
CY2012Q3 us-gaap Revenues
Revenues
577759
CY2012Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4960912
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-3385004
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.02
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82456708 shares
CY2013Q3 us-gaap Revenues
Revenues
7202083
CY2013Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
130368
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1867838
CY2012Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79971888 shares
CY2012Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.15
CY2012Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79971888 shares
CY2012Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.15
CY2012Q4 us-gaap Revenues
Revenues
1686406
CY2012Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13432485
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-12371188
CY2012Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
9500000
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.05
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85741278 shares
CY2013Q4 us-gaap Revenues
Revenues
1524137
CY2013Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4483217
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-4198032

Files In Submission

Name View Source Status
0001193125-14-097662-index-headers.html Edgar Link pending
0001193125-14-097662-index.html Edgar Link pending
0001193125-14-097662.txt Edgar Link pending
0001193125-14-097662-xbrl.zip Edgar Link pending
cris-20131231.xml Edgar Link completed
cris-20131231.xsd Edgar Link pending
cris-20131231_cal.xml Edgar Link unprocessable
cris-20131231_def.xml Edgar Link unprocessable
cris-20131231_lab.xml Edgar Link unprocessable
cris-20131231_pre.xml Edgar Link unprocessable
d635982d10k.htm Edgar Link pending
d635982dex21.htm Edgar Link pending
d635982dex231.htm Edgar Link pending
d635982dex311.htm Edgar Link pending
d635982dex312.htm Edgar Link pending
d635982dex321.htm Edgar Link pending
d635982dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g635982g52e56.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending